The New Obesity Drugs: What Cardiac Practitioners Need to Know

03/19/24 • 34 min

Please join our special guest Dr. Ian Neeland from University Hospitals in Cleveland, to discuss the intersection of obesity and cardiovascular disease, and specifically the roles of the new agents semaglutide and tirzepatide. We discuss the recent data on cardiovascular outcomes with these agents, assessing patient candidacy, and tips for initiating and monitoring therapy. We also reviewed the complementary role of bariatric surgery and pharmacotherapy to improve cardiac outcomes.
For more information, see the SELECT study.
For more information about the UH CINEMA program, click on this link.

Please subscribe to receive updated episodes automatically! Visit https://www.ohioacc.org/cardiohio-podcast/.
“Upbeat Party” by scottholmesmusic.com

03/19/24 • 34 min

CardiOhio Podcast - The New Obesity Drugs: What Cardiac Practitioners Need to Know

Transcript

Kanny00:00:12.169

So welcome back everyone to the CardioHop podcast. We're excited today to have a discussion about

Kanny00:00:20.190

metabolic aspects of, of obesity and the intersection with heart disease. And we're going to talk a little bit about some new agents that have been very popular in the cardiac world and the general medical world as well, as well as with the lay public in the management of overweight and obesity.

Generate a badge

Get a badge for your website that links back to this episode

Select type & size

Copy